Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at the 2021 Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
November 09, 2021 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash...
November 05, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib...
November 05, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the...
November 02, 2021 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
November 01, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021

-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride--...
October 21, 2021 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b...
October 18, 2021 16:07 ET | Source: Calithera Biosciences, Inc.

Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals

-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company’s precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib...
September 08, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...
September 02, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and...